Safety, Tolerability, and Immunogenicity of CYT004-MelQbG10 Vaccine With or Without Immunostimulating Adjuvant in HLA-A2 Positive Patients With Stage III/IV Malignant Melanoma
Phase of Trial: Phase II
Latest Information Update: 12 Nov 2010
At a glance
- Drugs CYT 004 MelQbG10 (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 12 Nov 2010 Actual end date (July 2010) added as reported by ClinicalTrials.gov.
- 12 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 May 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.